ARCH CV Signal Scuppers Blockbuster Hopes For Amgen/UCB's Evenity

 
• By Alexandra Shimmings

New Phase III data for the novel osteoporosis therapy romosozumab are set to delay its approval, reduce its commercial potential and open the market to rivals.

Ephesus
Crumbling ARCH: Data Reduce Likelhood Of Approval • Source: Shutterstock

More from Business

More from Scrip